Reducing HCV in Corrections: Part 2, Treatment and Prevention

Join us for this live, 45-minute, CME/CE/CPE-certified Webinar to find out how you can contribute to the goals of eliminating HCV infection among persons who are incarcerated. The presentation will focus on strategies to make HCV treatment in corrections settings more accessible and the critical role of harm reduction in preventing ongoing HCV transmission. 

Agenda

Welcome and Overview

Expanding HCV treatment access in corrections

Prioritizing HCV treatment for individual health and community prevention

Making harm reduction a core component of HCV prevention

Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Mark Sulkowski, MD

Professor of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and
Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty
Anne Spaulding, MD, MPH

Associate Professor
Department of Epidemiology
Rollins School of Public Health
Emory University
Infectious Disease Physician
Division of Infectious Disease
Department of Medicine
Emory School of Medicine
Atlanta, Georgia

Program Overview
The primary purpose of this program is to increase awareness of HCV elimination goals and provide clinicians with practical strategies for meeting these goals within their practice settings. The program focuses on 3 principal at-risk populations that are critical to national HCV elimination goals: people who inject drugs, people who are incarcerated, and men who have sex with men.

Goal Statement
The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.

Target Audience 
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Learning Objectives

  • Educate policy makers on strategies for expanding HCV treatment in corrections settings and associated cost and health benefits
  • Integrate harm reduction services into HCV prevention programs in correctional settings

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, American Society of Addiction Medicine, HealthHCV, and International Network for Hepatitis in Substance Users. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.

Pharmacist Continuing Education

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-919-L01-P)

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.